| Basics |
Intellia Therapeutics, Inc.
Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.
|
| IPO Date: |
May 6, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.9B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.13 | 3.19%
|
| Avg Daily Range (30 D): |
$0.98 | 5.09%
|
| Avg Daily Range (90 D): |
$0.55 | 3.63%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.14M |
| Avg Daily Volume (30 D): |
6.19M |
| Avg Daily Volume (90 D): |
4.87M |
| Trade Size |
| Avg Trade Size (Sh.): |
75 |
| Avg Trade Size (Sh.) (30 D): |
91 |
| Avg Trade Size (Sh.) (90 D): |
100 |
| Institutional Trades |
| Total Inst.Trades: |
4,667 |
| Avg Inst. Trade: |
$2.95M |
| Avg Inst. Trade (30 D): |
$2.84M |
| Avg Inst. Trade (90 D): |
$2.47M |
| Avg Inst. Trade Volume: |
.09M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.83M |
| Avg Closing Trade (30 D): |
$8.64M |
| Avg Closing Trade (90 D): |
$5.42M |
| Avg Closing Volume: |
150.36K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
$-.98
|
$-1.1
|
|
Diluted EPS
|
|
$-.98
|
$-1.1
|
|
Revenue
|
$
|
$ 14.25M
|
$ 16.63M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -101.26M
|
$ -114.33M
|
|
Operating Income / Loss
|
$
|
$ -110M
|
$ -120.81M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -32.66M
|
$ M
|
|
PE Ratio
|
|
|
|
|
|
|
